Identification of Allergen-reactive Antibodies in the Blood of Pollen Allergic Patients
- Conditions
- Pollen Allergy
- Registration Number
- NCT03727399
- Lead Sponsor
- Mabylon AG
- Brief Summary
The project examines the hypothesis that monoclonal allergen-neutralizing antibodies can be recombinantly produced from B lymphocytes isolated from pollen allergic patients. Patient samples suitable for antibody cloning are selected based on seroprofiling for the respective allergens. The study aims at isolating lymphocytes from patients with potential allergen-neutralizing IgG in serum and to clone antibodies from antibody gene sequences obtained from B cells of those patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ENROLLING_BY_INVITATION
- Sex
- All
- Target Recruitment
- 300
- History of allergic rhinitis, conjunctivitis or asthma due to sensitization to grass- or birch Allergens
- Male or female patients older than 18 years
- Written informed consent for providing blood and also to allow experimental manipulation
- Age < 18 years
- Any corticosteroids within the last three days
- Oral corticosteroid therapy within the last ten days
- Parenteral depot corticosteroids within the last three months
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Antibody profiling October 2018 - September 2021 Analysis and IgG profiling of specific antibodies binding major grass- and tree-pollen allergens in allergic patients.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
Immunologie Zentrum Zürich
🇨🇭Zürich, Switzerland
Immunologie Zentrum Zürich🇨🇭Zürich, Switzerland